Abstract
α-Methyl-l-tyrosine (AMT) has a high affinity for the cancer-specific l-type amino acid transporter 1 (LAT1). Therefore, we established an anti-cancer therapy, with 211At-labeled α-methyl-l-tyrosine (211At-AAMT) as a carrier of 211At into tumors. 211At-AAMT had high affinity for LAT1, inhibited tumor cell growth, and induced DNA double-stranded breaks in vitro. We evaluated the accumulation of 211At-AAMT in vivo and the role of LAT1. Treatment with 0.4 MBq/mouse 211At-AAMT inhibited tumor growth in the PANC-1 tumor model and 1 MBq/mouse 211At-AAMT inhibited metastasis in the lung of the B16F10 metastasis model. Our results suggested that 211At would be useful for anti-cancer therapy and that LAT1 is suitable as a target for radionuclide therapy.
Author supplied keywords
Cite
CITATION STYLE
Kaneda-Nakashima, K., Zhang, Z. J., Manabe, Y., Shimoyama, A., Kabayama, K., Watabe, T., … Shinohara, A. (2021). α-Emitting cancer therapy using 211At-AAMT targeting LAT1. Cancer Science, 112(3), 1132–1140. https://doi.org/10.1111/cas.14761
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.